A Previously Banned Apple Watch Health Feature May Soon Make a Comeback


The Apple Watch‘s blood oxygen sensor has been at the center of what feels like a never-ending tennis match of legal back-and-forth.

In 2020, the Apple Watch Series 6 launched with the sensor that measures your blood’s oxygen saturation (SpO2), which is how much oxygen red blood cells pick up from your lungs and transport to the rest of your body. That same year, global medical technology company Masimo filed a lawsuit claiming that Apple’s sensor infringed its patents. In 2023, the US International Trade Commission sided with Masimo and imposed an import ban on Apple Watch Series 9 and Ultra 2 models.

However, on Friday, the ITC declined Masimo’s request for another import ban on the Apple Watch and said it wouldn’t review a preliminary ruling finding that the redesigned Apple Watch doesn’t infringe Masimo’s patents. This is a major win for Apple. 

Unless Masimo decides to appeal the decision, Apple can bring blood oxygen monitoring back to its devices. 

But based on the history of this case, it may not be the end of this match. 

The history of Apple’s blood oxygen ban

The ITC became involved in the Masimo and Apple legal battle in 2021, and in January 2023, it upheld that Apple violated Masimo’s patents. Then, in December 2023, the ITC banned Apple from importing its watches, including the Series 9 and Ultra 2, into the US. 

To avoid the ban, Apple disabled blood oxygen sensing on its devices. 

Ahead of the Apple Watch Series 11 launch, Apple reintroduced blood oxygen sensing in August 2025, which was approved by the US Customs and Border Protection. It got around the ban by using a paired iPhone to display blood oxygen levels instead of the Apple Watch. Masimo sued US Customs over this decision. 

The blood oxygen tab in the iPhone Health app.

If relaunched, you’d be able to view your blood oxygen levels in the iPhone’s Health app.

Apple

In November 2025, a jury for the US District Court for the Central District of California found that Apple infringed one of Masimo’s patents and awarded the company $634 million in damages. Apple told AppleInsider that it plans to appeal, claiming that the patent expired in 2022.

Though the ITC has rejected another ban on Apple’s blood oxygen feature and declined Masimo’s request to review the ruling in Apple’s favor, Masimo may continue the battle, especially given its November win, after which the company released a statement saying, “We remain committed to defending our IP [intellectual property] rights moving forward.”

An Apple representative didn’t immediately respond to a request for comment. Masimo declined to comment.

In the meantime, if your curiosity gets the best of you, you could always purchase a pulse oximeter. It’s a device that estimates your blood oxygen level by measuring the light that passes through your finger. No messy legal battles involved.





Source link

Leave a Reply

Subscribe to Our Newsletter

Get our latest articles delivered straight to your inbox. No spam, we promise.

Recent Reviews







Virtually every new SUV will depreciate in value over its life as the miles rack up and components start to wear out. However, some of them depreciate much faster than others. At one end of the spectrum, there are some models from the likes of Cadillac, Tesla, and Infiniti, all of which can lose close to two-thirds of their value after just half a decade on the road. That makes them some of the worst-depreciating SUVs on the market. At the other end, there are SUVs like the Toyota Land Cruiser.

The exact resale value of any used car will depend on factors like its trim, condition, and mileage, but on average, Land Cruiser owners can expect a higher trade-in value than most rivals will fetch. According to data from CarEdge, a new Land Cruiser can be expected to lose around 35% of its original value after five years on the road, assuming it covers around 13,500 miles annually.

Estimates from iSeeCars make for equally encouraging reading for Land Cruiser owners, with the outlet estimating that after five years, a new example will lose just 34.4% of its sticker price. Even after seven years on the road, iSeeCars estimates that the average Land Cruiser will still be worth a little over half of what buyers originally paid for it.

The Land Cruiser holds its value well

The estimate from iSeeCars puts the Land Cruiser slightly ahead of average for value retention in the large hybrid SUV segment, and significantly ahead of the overall market average for new SUVs. According to the same data, the average new SUV can expect to lose 44.9% of its value over the same period, over 10% more than the Land Cruiser. That said, a different Toyota SUV is forecast to retain even more of its value.

Since the 2025 model year, both the Land Cruiser and the 4Runner have shared their platform and hybrid powertrains. However, according to current estimates, the 4Runner is the clear winner when it comes to resale value. Data from iSeeCars forecasts that a new, non-hybrid 4Runner is likely to lose only 25.4% of its value after its first five years, and CarEdge predicts almost exactly the same figure. According to the former outlet, a hybrid 4Runner will lose slightly more of its value over the same timeframe, shedding 28.6% on average.

While the 4Runner is the better choice purely for value retention, that only forms part of the equation for most buyers. The Land Cruiser remains appealing thanks to its mix of off-road capability and on-road refinement, with even the base 2026 trim offering plenty of standard features, despite missing out on the luxuries that higher trims include.





Source link